Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125783542 | 12578354 | 2 | F | 20160222 | 20160906 | 20160721 | 20160914 | EXP | FR-ASTRAZENECA-2016SE52486 | ASTRAZENECA | 23976.00 | DY | F | Y | 0.00000 | 20160914 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125783542 | 12578354 | 1 | PS | FASLODEX | FULVESTRANT | 1 | Intramuscular | 250 MG TWICE A DAY ON DAYS 1/15/28 AND THEN MONTHLY | 21344 | INJECTION | |||||||||
| 125783542 | 12578354 | 2 | SS | PALBOCICLIB | PALBOCICLIB | 1 | Oral | N | U | N01734 | 0 | 125 | MG | CAPSULE | QD | ||||
| 125783542 | 12578354 | 3 | SS | PALBOCICLIB | PALBOCICLIB | 1 | Oral | N | U | N01732 | 0 | 125 | MG | CAPSULE | QD | ||||
| 125783542 | 12578354 | 4 | SS | PALBOCICLIB | PALBOCICLIB | 1 | Oral | N | U | N01732 | 0 | 100 | MG | CAPSULE | QD | ||||
| 125783542 | 12578354 | 5 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | ||||||||||||
| 125783542 | 12578354 | 6 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 125783542 | 12578354 | 7 | C | INNOHEP | TINZAPARIN SODIUM | 1 | Subcutaneous | 0 | |||||||||||
| 125783542 | 12578354 | 8 | C | LOSARTAN. | LOSARTAN | 1 | 0 | 1 | DF | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125783542 | 12578354 | 1 | Breast cancer |
| 125783542 | 12578354 | 2 | Breast cancer |
| 125783542 | 12578354 | 3 | Breast cancer |
| 125783542 | 12578354 | 4 | Breast cancer |
| 125783542 | 12578354 | 5 | Hypertension |
| 125783542 | 12578354 | 6 | Gastrooesophageal reflux disease |
| 125783542 | 12578354 | 7 | Pulmonary embolism |
| 125783542 | 12578354 | 8 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125783542 | 12578354 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125783542 | 12578354 | Haemoglobin decreased | |
| 125783542 | 12578354 | Neutropenia | |
| 125783542 | 12578354 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125783542 | 12578354 | 1 | 20160224 | 0 | ||
| 125783542 | 12578354 | 2 | 20160224 | 20160323 | 0 | |
| 125783542 | 12578354 | 3 | 20160406 | 20160504 | 0 | |
| 125783542 | 12578354 | 4 | 20160511 | 0 | ||
| 125783542 | 12578354 | 7 | 201404 | 0 | ||
| 125783542 | 12578354 | 8 | 201607 | 0 |